{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T05:25:31Z","timestamp":1731043531983,"version":"3.28.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00108-024-01780-6","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T08:02:08Z","timestamp":1727164928000},"page":"1082-1091","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impfungen f\u00fcr neu- und wiederauftretende Viruserkrankungen","Vaccinations for emerging and re-emerging viral diseases"],"prefix":"10.1007","volume":"65","author":[{"given":"Hanna-Marie","family":"Weichel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Till","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"1780_CR1","unstructured":"WHO Prioritizing diseases for research and development in emergency contexts. https:\/\/www.who.int\/activities\/prioritizing-diseases-for-research-and-development-in-emergency-contexts. Zugegriffen: 23. Juni 2024"},{"issue":"10","key":"1780_CR2","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1080\/21645515.2019.1649532","volume":"15","author":"A Fathi","year":"2019","unstructured":"Fathi\u00a0A, Dahlke\u00a0C, Addo\u00a0MM (2019) Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. Hum Vaccin Immunother 15(10):2269\u20132285","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"1780_CR3","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1016\/S1473-3099(23)00376-6","volume":"24","author":"MA Moso","year":"2024","unstructured":"Moso\u00a0MA et\u00a0al (2024) Prevention and post-exposure management of occupational exposure to Ebola virus. Lancet Infect Dis 24(2):e93\u2013e105","journal-title":"Lancet Infect Dis"},{"key":"1780_CR4","doi-asserted-by":"publisher","first-page":"1178122X1984992","DOI":"10.1177\/1178122X19849927","volume":"10","author":"S Languon","year":"2019","unstructured":"Languon\u00a0S, Quaye\u00a0O (2019) Filovirus disease outbreaks: a\u00a0chronological overview. Virology 10:1178122X19849927","journal-title":"Virology"},{"issue":"10068","key":"1780_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","volume":"389","author":"AM Henao-Restrepo","year":"2017","unstructured":"Henao-Restrepo\u00a0AM et\u00a0al (2017) Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 389(10068):505\u2013518","journal-title":"Lancet"},{"key":"1780_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081263","author":"MM Tiemessen","year":"2022","unstructured":"Tiemessen\u00a0MM et\u00a0al (2022) Protection against Marburg virus and Sudan virus in NHP by an adenovector-based trivalent vaccine regimen is correlated to humoral immune response levels. Vaccines. https:\/\/doi.org\/10.3390\/vaccines10081263","journal-title":"Vaccines"},{"key":"1780_CR7","unstructured":"WHO (2022) Summary of the evaluations and recommendations on the three Sudan ebolavirus vaccines that are candidates for inclusion in the planned ring vaccination trial in Uganda (\u201cTokomeza Ebola). https:\/\/cdn.who.int\/media\/docs\/default-source\/blue-print\/who-vaccine-prioritization-report-uganda-ebola-trial-nov-16-2022.pdf. Zugegriffen: 23. Mai 2024"},{"issue":"12","key":"1780_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/S1473-3099(23)00344-4","volume":"23","author":"B Mwesigwa","year":"2023","unstructured":"Mwesigwa\u00a0B et\u00a0al (2023) Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a\u00a0phase\u00a01, open-label, dose-escalation clinical trial. Lancet Infect Dis 23(12):1408\u20131417","journal-title":"Lancet Infect Dis"},{"issue":"10373","key":"1780_CR9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(22)02400-X","volume":"401","author":"MJ Hamer","year":"2023","unstructured":"Hamer\u00a0MJ et\u00a0al (2023) Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type\u00a03-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a\u00a0first-in-human, phase\u00a01, open-label, dose-escalation trial. Lancet 401(10373):294\u2013302","journal-title":"Lancet"},{"issue":"10","key":"1780_CR10","doi-asserted-by":"publisher","first-page":"e0274906","DOI":"10.1371\/journal.pone.0274906","volume":"17","author":"V Bockstal","year":"2022","unstructured":"Bockstal\u00a0V et\u00a0al (2022) First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: a\u00a0randomized, controlled study. PLoS ONE 17(10):e274906","journal-title":"PLoS ONE"},{"issue":"10438","key":"1780_CR11","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0140-6736(24)00641-X","volume":"403","author":"A Zumla","year":"2024","unstructured":"Zumla\u00a0A et\u00a0al (2024) Anticipating a\u00a0MERS-like coronavirus as a\u00a0potential pandemic threat. Lancet 403(10438):1729\u20131731","journal-title":"Lancet"},{"issue":"10048","key":"1780_CR12","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/S0140-6736(16)30623-7","volume":"388","author":"SY Cho","year":"2016","unstructured":"Cho\u00a0SY et\u00a0al (2016) MERS-CoV outbreak following a\u00a0single patient exposure in an emergency room in South Korea: an epidemiological outbreak study. Lancet 388(10048):994\u20131001","journal-title":"Lancet"},{"issue":"9","key":"1780_CR13","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","volume":"19","author":"K Modjarrad","year":"2019","unstructured":"Modjarrad\u00a0K et\u00a0al (2019) Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a\u00a0phase\u00a01, open-label, single-arm, dose-escalation trial. Lancet Infect Dis 19(9):1013\u20131022","journal-title":"Lancet Infect Dis"},{"key":"1780_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(20)30248-6","author":"T Koch","year":"2020","unstructured":"Koch\u00a0T et\u00a0al (2020) Safety and immunogenicity of a\u00a0modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase\u00a01\u00a0trial. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/s1473-3099(20)30248-6","journal-title":"Lancet Infect Dis"},{"key":"1780_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(20)30160-2","author":"PM Folegatti","year":"2020","unstructured":"Folegatti\u00a0PM et\u00a0al (2020) Safety and immunogenicity of a\u00a0candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a\u00a0dose-escalation, open-label, non-randomised, uncontrolled, phase\u00a01\u00a0trial. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/s1473-3099(20)30160-2","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1780_CR16","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/S2666-5247(21)00193-2","volume":"3","author":"M Bosaeed","year":"2022","unstructured":"Bosaeed\u00a0M et\u00a0al (2022) Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase\u00a01b\u00a0trial. Lancet Microbe 3(1):e11\u2013e20","journal-title":"Lancet Microbe"},{"issue":"6","key":"1780_CR17","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41564-024-01690-1","volume":"9","author":"B Moss","year":"2024","unstructured":"Moss\u00a0B (2024) Understanding the biology of monkeypox virus to prevent future outbreaks. Nat Microbiol 9(6):1408\u20131416","journal-title":"Nat Microbiol"},{"issue":"6","key":"1780_CR18","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.cell.2024.01.017","volume":"187","author":"A Zuiani","year":"2024","unstructured":"Zuiani\u00a0A et\u00a0al (2024) A\u00a0multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease. Cell 187(6):1363\u20131373.e12","journal-title":"Cell"},{"issue":"12","key":"1780_CR19","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1038\/nm1141","volume":"10","author":"P Palese","year":"2004","unstructured":"Palese\u00a0P (2004) Influenza: old and new threats. Nat Med 10(12):S82\u20137","journal-title":"Nat Med"},{"issue":"1","key":"1780_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","volume":"4","author":"F Krammer","year":"2018","unstructured":"Krammer\u00a0F et\u00a0al (2018) Influenza. Nat Rev Dis Primers 4(1):3","journal-title":"Nat Rev Dis Primers"},{"key":"1780_CR21","unstructured":"CDC (2024) Technical report: june 2024 highly pathogenic avian influenza\u00a0A(H5N1) viruses. https:\/\/www.cdc.gov\/bird-flu\/php\/technical-report\/h5n1-06052024.html. Zugegriffen: 23. Juni 2024"},{"issue":"1","key":"1780_CR22","doi-asserted-by":"publisher","first-page":"2332667","DOI":"10.1080\/22221751.2024.2332667","volume":"13","author":"JA Pulit-Penaloza","year":"2024","unstructured":"Pulit-Penaloza\u00a0JA et\u00a0al (2024) Highly pathogenic avian influenza A(H5N1) virus of clade 2.3.4.4b isolated from a\u00a0human case in Chile causes fatal disease and transmits between co-housed ferrets. Emerg Microbes Infect 13(1):2332667","journal-title":"Emerg Microbes Infect"},{"key":"1780_CR23","unstructured":"CDC (2023) Technical report: june 2023 highly pathogenic avian influenza\u00a0A(H5N1) viruses. https:\/\/www.cdc.gov\/bird-flu\/php\/technical-report\/h5n1-070723.html. Zugegriffen: 23. Juni 2024"},{"issue":"6622","key":"1780_CR24","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","volume":"378","author":"CP Arevalo","year":"2022","unstructured":"Arevalo\u00a0CP et\u00a0al (2022) A\u00a0multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378(6622):899\u2013904","journal-title":"Science"},{"issue":"9","key":"1780_CR25","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nm.3927","volume":"21","author":"HM Yassine","year":"2015","unstructured":"Yassine\u00a0HM et\u00a0al (2015) Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 21(9):1065\u20131070","journal-title":"Nat Med"},{"key":"1780_CR26","doi-asserted-by":"crossref","unstructured":"Corbett KS et\u00a0al (2019) Design of nanoparticulate group\u00a02 influenza virus hemagglutinin stem antigens that activate unmutated ancestor B\u00a0cell receptors of broadly neutralizing antibody lineages. mBio","DOI":"10.1101\/497123"},{"issue":"1","key":"1780_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","volume":"27","author":"R Nachbagauer","year":"2021","unstructured":"Nachbagauer\u00a0R et\u00a0al (2021) A\u00a0chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a\u00a0randomized, placebo-controlled phase\u00a0I trial. Nat Med 27(1):106\u2013114","journal-title":"Nat Med"},{"issue":"1","key":"1780_CR28","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1038\/s41467-024-48555-z","volume":"15","author":"C Furey","year":"2024","unstructured":"Furey\u00a0C et\u00a0al (2024) Development of a\u00a0nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus. Nat Commun 15(1):4350","journal-title":"Nat Commun"},{"key":"1780_CR29","unstructured":"The influenza vaccine roadmap initiative (2024) Universal influenza vaccine technology landscape. https:\/\/ivr.cidrap.umn.edu\/universal-influenza-vaccine-technology-landscape. Zugegriffen: 23. Juni 2024"},{"key":"1780_CR30","unstructured":"WHO (2024) Global arbovirus initiative: preparing for the next pandemic by tackling mosquito-borne viruses with epidemic and pandemic potential. https:\/\/www.who.int\/publications\/i\/item\/9789240088948. Zugegriffen: 23. Juni 2024"},{"key":"1780_CR31","unstructured":"WHO (2023) Dengue\u2014global situation. https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2023-DON498. Zugegriffen: 21. Dez. 2023"},{"issue":"8","key":"1780_CR32","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/v12080829","volume":"12","author":"H Harapan","year":"2020","unstructured":"Harapan\u00a0H et\u00a0al (2020) Dengue: a\u00a0minireview. Viruses 12(8):829","journal-title":"Viruses"},{"key":"1780_CR33","unstructured":"WHO (2023) Dengue and severe dengue. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue. Zugegriffen: 17. M\u00e4rz 2023"},{"key":"1780_CR34","unstructured":"Sanofi (2024) Information on Dengvaxia. https:\/\/www.sanofi.com\/en\/our-company\/social-impact\/responsible-business-values\/information-on-dengvaxia. Zugegriffen: 23. Juni 2024"},{"key":"1780_CR35","doi-asserted-by":"publisher","first-page":"1202055","DOI":"10.3389\/fimmu.2023.1202055","volume":"14","author":"Y-C Dai","year":"2023","unstructured":"Dai\u00a0Y\u2011C et\u00a0al (2023) Identification of prior dengue-na\u00efve Dengvaxia recipients with an increased risk for symptomatic dengue during fever surveillance in the Philippines. Front Immunol 14:1202055","journal-title":"Front Immunol"},{"issue":"4","key":"1780_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","volume":"379","author":"S Sridhar","year":"2018","unstructured":"Sridhar\u00a0S et\u00a0al (2018) Effect of dengue serostatus on dengue vaccine safety and efficacy. N\u00a0Engl J Med 379(4):327\u2013340","journal-title":"N Engl J Med"},{"issue":"21","key":"1780_CR37","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","volume":"381","author":"S Biswal","year":"2019","unstructured":"Biswal\u00a0S et\u00a0al (2019) Efficacy of a\u00a0tetravalent dengue vaccine in healthy children and adolescents. N\u00a0Engl J Med 381(21):2009\u20132019","journal-title":"N Engl J Med"},{"issue":"2","key":"1780_CR38","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","volume":"12","author":"V Tricou","year":"2024","unstructured":"Tricou\u00a0V et\u00a0al (2024) Long-term efficacy and safety of a\u00a0tetravalent dengue vaccine (TAK-003): 4.5-year results from a\u00a0phase\u00a03, randomised, double-blind, placebo-controlled trial. Lancet Glob Health 12(2):e257\u2013e270","journal-title":"Lancet Glob Health"},{"key":"1780_CR39","unstructured":"PEI (2024) Denguefieber-Impfstoffe. https:\/\/www.pei.de\/DE\/arzneimittel\/impfstoffe\/denguefieber\/dengue-inhalt.html"},{"issue":"10394","key":"1780_CR40","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","volume":"401","author":"M Schneider","year":"2023","unstructured":"Schneider\u00a0M et\u00a0al (2023) Safety and immunogenicity of a\u00a0single-shot live-attenuated chikungunya vaccine: a\u00a0double-blind, multicentre, randomised, placebo-controlled, phase\u00a03\u00a0trial. Lancet 401(10394):2138\u20132147","journal-title":"Lancet"},{"issue":"1","key":"1780_CR41","doi-asserted-by":"publisher","first-page":"2301573","DOI":"10.1080\/21505594.2023.2301573","volume":"15","author":"H Ly","year":"2024","unstructured":"Ly\u00a0H (2024) Ixchiq (VLA1553): the first FDA-approved vaccine to prevent disease caused by Chikungunya virus infection. Virulence 15(1):2301573","journal-title":"Virulence"},{"key":"1780_CR42","unstructured":"European Commission (2024) Commission authorises Chikungunya vaccine and funds new mosquito eradication programme. https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/ip_24_3502. Zugegriffen: 12. Juli 2024"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01780-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01780-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01780-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T18:01:53Z","timestamp":1731002513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01780-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1780"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01780-6","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"assertion":[{"value":"7 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.-M.\u00a0Weichel und T.\u00a0Koch geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}